All In Biotech

NDA 020193 · Janssen Pharms

Elmiron

Pentosan Polysulfate Sodium · Oral

NovelOrphan

Last checked: Nov 19, 2026Latest source record: Mar 12, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Sep 26, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9

5 Phase 3, 2 recruiting

FAERS reports

6,930

4,861 serious, 120 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 18, 2024.

INDICATIONS AND USAGE ELMIRON ® (pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 26, 1996 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
  • ELMIRON · PENTOSAN POLYSULFATE SODIUM 100MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pentosan Polysulfate" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,404
  • maculopathy1,398
  • retinal pigmentation607
  • dry age-related macular degeneration562
  • pigmentary maculopathy470
  • drug ineffective354
  • pain304
  • nausea278
  • product use issue272
  • headache237
  • cystitis interstitial214
  • macular degeneration214

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200441
200551
200657
200752
200869
200970
2010112
2011169
2012157
2013146
2014170
2015565
2016355
2017276
2018331
2019334
2020499
2021686
20221,541
2023601
2024331
2025223
202694

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Elmiron (Pentosan Polysulfate Sodium)

2024 spending

$52.0M

Beneficiaries

9,098

42,953 claims

Per beneficiary

$5,711

$11.01 per unit

View as table
YearSpending
2020$83,470,502
2021$63,370,871
2022$58,415,643
2023$55,269,822
2024$51,962,064

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 76 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.